Pulmonary Hypertension: A Contraindication for Lung Volume Reduction Surgery?
Historically, pulmonary hypertension (PH) is considered as one of the contraindications for lung volume reduction surgery (LVRS). Newer studies have shown that LVRS is successful in select emphysema patients with PH. In-hospital and one-year functional and quality of life (QOL) outcomes were studied in patients with PH post-LVRS. PH was defined as pulmonary artery pressure (PAP) > 35 mmHg by right heart catheterization (RHC) where available or else > 35 mmHg by ECHO. Of 124 patients who underwent LVRS, 56 (45%) had PH (mean PAP: 41 mmHg) with 48 mild-to-moderate and 8 having severe PH. In-hospital outcomes were similar between patients with and without PH: hours of artificial ventilation (1.8 vs 0.06, p-value-0.882), days in intensive care (4 vs 6, p-value-0.263), prolonged air leak (12% vs 19%, p-value-0.402), and days of hospital stay (13 vs 16, p-value-0.072). Lung function improved significantly at one-year follow-up in patients with PH: FEV1% (26 vs 38, p-value-0. 001), FVC% (62 vs 90, p-value-0. 001), RV% (224 vs 174, p-value-0. 001), and DLCO% (36 vs 43, p-value-0. 001), 6MWD test (1104 vs 1232, p-value-0.001), and QOL utility scores (0.67 vs 0.77, p-value-0. 001). There were no differences in in-hospital, baseline, and follow-up functional and QOL outcomes between patients with and without PH. In this small single institutional cohort, patients undergoing LVRS for emphysema with PH had similar outcomes to that of patients without PH. LVRS may be a potential option for select emphysema patients with PH.